Bausch & Lomb (TSX:BLCO) Total Receivables : C$1,446 Mil (As of Mar. 2025)

View and export this data going back to 2022. Start your Free Trial

What is Bausch & Lomb Total Receivables?

Bausch & Lomb's Total Receivables for the quarter that ended in Mar. 2025 was C$1,446 Mil.

Bausch & Lomb Total Receivables Historical Data

The historical data trend for Bausch & Lomb's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bausch & Lomb Total Receivables Chart

Bausch & Lomb Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Receivables

Get a 7-Day Free Trial

826.18

922.88

983.55

1,125.60

1,461.74

Bausch & Lomb Quarterly Data
	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Receivables	Get a 7-Day Free Trial														1,245.31	1,351.31	1,277.39	1,461.74	1,445.65

Bausch & Lomb Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Bausch & Lomb Total Receivables Related Terms

Thank you for viewing the detailed overview of Bausch & Lomb's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Bausch & Lomb Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bausch & Lomb Corp (TSX:BLCO) » Definitions » Total Receivables

Comparable Companies

Traded in Other Exchanges

BLCO:USA

Address

520 Applewood Crescent, Vaughan, ON, CAN, L4K 4B4

Website

https://www.bausch.com

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Executives